ALPK3截短变异是常染色体显性肥厚型心肌病的病因
本研究旨在确定 heterozygous ALPK3 truncating variants (ALPK3tv) 在肥厚型心肌病(HCM)患者中的频率,并通过独立队列的负荷测试和家系共分离研究确认其致病性。在770例HCM先证者中发现12例(1.56%)携带ALPK3tv,验证队列2047例中32例(1.56%)携带,OR值均显著高于gnomAD人群;ALPK3tv携带者具有独特的HCM表型,包括更高的心尖/向心性肥厚和短PR间期比例,且预后与肌节变异携带者相似。结论认为ALPK3tv是致病性的,并与特征性HCM表型共分离。
要点
- ALPK3tv在HCM患者中频率约1.56%,显著高于一般人群。
- ALPK3tv携带者心尖/向心性肥厚和短PR间期更常见。
- ALPK3tv携带者预后与肌节变异阳性者相似,但不同于肌节变异阴性者。
核心结论
- Heterozygous ALPK3tv是致病性的,并与特征性HCM表型共分离。
研究设计与样本
- 发现队列纳入770例HCM先证者,验证队列纳入2047例HCM先证者,并与gnomAD人群比较频率。
- 对7个携带ALPK3tv的家系进行共分离分析,计算连锁对数得分(LOD)。
- 与1679例基因分型的HCM患者(肌节变异阳性或阴性)比较表型和预后。
主要发现
- 发现队列中12例(1.56%)携带ALPK3tv,OR 16.11(95%CI 7.94-30.02,P=8.05e-11)。
- 验证队列中32例(1.56%)携带ALPK3tv,OR 16.17(95%CI 10.31-24.87,P<2.2e-16)。
- 7个家系的共分离LOD得分为2.99。
- ALPK3tv携带者心尖/向心性肥厚比例为60%(P<0.001),短PR间期比例为10%(P=0.009)。
- 基线左室收缩功能不全(6%)和非持续性室速(31%)与肌节变异阳性者相似;随访5.3±5.7年后,4例(9%)死亡或心脏移植,与肌节变异阴性者相比log-rank P=0.012,与肌节变异阳性者相比P=0.425。
临床怎么用
- 对HCM患者可考虑进行ALPK3tv基因检测,尤其具有心尖/向心性肥厚和短PR间期表型者。
- ALPK3tv携带者的管理和预后评估可参考肌节变异阳性HCM患者。
局限性
- 研究为观察性设计,样本以先证者为主,外推性需进一步验证。
- 未报告ALPK3tv对治疗反应的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to determine the frequency of heterozygous truncating ALPK3 variants (ALPK3tv) in patients with hypertrophic cardiomyopathy (HCM) and confirm their pathogenicity using burden testing in independent cohorts and family co-segregation studies. METHODS AND RESULTS: In a discovery cohort of 770 index patients with HCM, 12 (1.56%) were heterozygous for ALPK3tv [odds ratio(OR) 16.11, 95% confidence interval (CI) 7.94-30.02, P = 8.05e-11] compared to the Genome Aggregation Database (gnomAD) population. In a validation cohort of 2047 HCM probands, 32 (1.56%) carried heterozygous ALPK3tv (OR 16.17, 95% CI 10.31-24.87, P < 2.2e-16, compared to gnomAD). Combined logarithm of odds score in seven families with ALPK3tv was 2.99. In comparison with a cohort of genotyped patients with HCM (n = 1679) with and without pathogenic sarcomere gene variants (SP+ and SP-), ALPK3tv carriers had a higher prevalence of apical/concentric patterns of hypertrophy (60%, P < 0.001) and of a short PR interval (10%, P = 0.009). Age at diagnosis and maximum left ventricular wall thickness were similar to SP- and left ventricular systolic impairment (6%) and non-sustained ventricular tachycardia (31%) at baseline similar to SP+. After 5.3 ± 5.7 years, 4 (9%) patients with ALPK3tv died of heart failure or had cardiac transplantation (log-rank P = 0.012 vs. SP- and P = 0.425 vs. SP+). Imaging and histopathology showed extensive myocardial fibrosis and myocyte vacuolation. CONCLUSIONS: Heterozygous ALPK3tv are pathogenic and segregate with a characteristic HCM phenotype.
引用
- Lopes LR, Garcia-Hernández S, Lorenzini M, et al. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. Eur Heart J. 2021. PMID: 34263907. doi:10.1093/eurheartj/ehab424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。